GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$39.16 USD
+0.26 (0.67%)
Updated Jul 12, 2024 03:59 PM ET
Pre-Market: $39.05 -0.11 (-0.28%) 9:08 AM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.16 USD
+0.26 (0.67%)
Updated Jul 12, 2024 03:59 PM ET
Pre-Market: $39.05 -0.11 (-0.28%) 9:08 AM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment
by Zacks Equity Research
Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GSK (GSK) closed at $35.30, marking a +0.89% move from the previous day.
Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study
by Zacks Equity Research
Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.
GSK (GSK) Stock Moves -0.81%: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $35.63 in the latest trading session, marking a -0.81% move from the prior day.
5 Momentum Stock Bargains Hunters Would Love Chasing
by Debdutta Sinha
Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
by Zacks Equity Research
Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
by Zacks Equity Research
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates
by Kinjel Shah
A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.
GSK & Others Get Relief as US Court Dismisses Zantac Litigation
by Zacks Equity Research
A U.S. district court dismisses thousands of lawsuits involving Zantac. Relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE).
Pfizer (PFE) RSV Vaccine Candidate BLA Gets FDA's Priority Tag
by Zacks Equity Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for RSV vaccine candidate in older adults is expected in May 2023.
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
by Zacks Equity Research
GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
Why Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion
by Zacks Equity Research
Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
by Kinjel Shah
Merck (MRK) offers to buy Imago Biosciences (IMGO). The European Commission approves AbbVie's (ABBV) immunology medicine, Skyrizi for Crohn's disease.
GSK to Withdraw Blenrep From U.S. Market on FDA Request
by Zacks Equity Research
GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.
Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?
by Zacks Equity Research
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.
The Zacks Analyst Blog Highlights Wells Fargo, Honeywell International, Northrop Grumman, The Travelers Companies and GSK
by Zacks Equity Research
Wells Fargo, Honeywell International, Northrop Grumman, The Travelers Companies and GSK are included in this Analyst Blog.
Top Stock Reports for Wells Fargo, Honeywell & Northrop Grumman
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo & Company (WFC), Honeywell International Inc. (HON) and Northrop Grumman Corporation (NOC).
Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine
by Zacks Equity Research
Sanofi (SNY) and partner GSK's COVID-19 vaccine receives authorization in the European Union for use as a booster in adults aged 18 years and older.
Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine
by Kinjel Shah
Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.
Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sales of GSK's vaccine segment, especially meningitis and influenza vaccines, are likely to have been an important contributor to third-quarter 2022 sales.